DRC Antigen Expression in B-Cell Lymphomas

Abstract

DRC (dendritic reticulum cell) antigen expression was studied in 38 cases of B-cell lymphomas including follicular lymphoma. The results of this study showed DRC-1 to be expressed in 1/3 of small lymphocytic; 3/3 of mantle zone lymphoma (MZL); 10/10 of follicular, small cleaved; 6/7 of follicular, mixed; 1/2 of follicular, large cell lymphomas. However, DRC-1 was not expressed in any of diffuse, small cleaved (0/6) and diffuse, large cell (0/6). Although S-100 protein was positive in the majority of these DRC-1-positive cases on the paraffin embedded specimens, positive nodules were less intense and smaller in number compared with those of DRC-1 on frozen tissue specimens. These results suggest that in case of small lymphocytic lymphoma found to be positive for DRC-1, the networks of the DRCs are expressed in the pseudofollicular proliferation centers. This study also suggests that the networks of the DRCs newly appear accompanying the neoplastic growth rather than originating from residual germinal centers, and that neoplastic small cleaved cells play a major role in inducing the DRCs in the positive cases of follicular lymphoma, MZL, and small lymphocytic lymphoma.

Primary hepatic marginal zone B-cell lymphoma with mantle cell lymphoma phenotype

“…The CD5+/DRC -I+/slgD-+/LN2 + findings in our patient imply that this is MCL [6,8,13,14,15]. The ALP+/cyclin DI-findings and the lymphoepithelial lesions with bile ducts in the patient imply that this is a marginal zone B-cell lymphoma [10,11].…”

“…MCL is characterized by the t (11;14) translocation and its molecular counterpart bcl-1 rearrangement, which may result in an overexpression of the PRAD-1/cyclin D1 gene [3,4,21] and cyclin DI protein expression [17,23]. Extranodal MCL has been reported [8,14,15,16,19]. However, to our knowledge hepatic MCL has not been reported previously.…”

Follicular dendritic cells in bone marrow lymphoproliferative diseases: an immunohistochemical study including a new paraffin‐resistant monoclonal antibody, DR53

“…The relationship noticed between the tumour mass of low grade B-cell lymphomas and the number and size of the follicular dendritic cell clusters, favours the view that follicular dendritic cells progressively develop as the neoplastic process spreads 25 . Together with the results observed in high grade B-cell lymphoma and in reactive bone marrows, it could support the hypothesis that the presence of follicular dendritic cells in bone marrow lymphoid infiltrates is not strictly linked to a malignant process, but possibly to a long-lasting chronic proliferation or reaction, as opposed to an acute proliferation or a transitory reaction.…”

Immunohistochemical Characteristics of Monocytoid B Cell Lymphoma, Mantle Zone Lymphoma, Small Lymphocytic Lymphoma (or B Chronic Lymphocytic Leukemia), and Hairy Cell Leukemia

“…In contrast, DRC-1 was not expressed in the other three types of lym phomas, except in 1 case of SL (case 14). We performed DRC staining with S-100 protein on the paraffin sections [20] of this particular case of SL and found that DRC-1 was positive in pseudofollicular proliferation centers. There fore, of the four lymphoma types, we consider DRC-1 pos itivity to be a characteristic of MZL.…”